Navigation Links
AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Date:3/3/2008

QUEBEC CITY and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS;TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, and Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that they have entered into a definitive purchase and sale agreement with respect to all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine for an aggregate purchase price of Cdn$9.125 million payable in cash, subject to certain post-closing purchase price adjustments. Miltefosine, sold under the brand name Impavido(R) throughout the world, recorded revenues of Euro 2.5 million in 2007. Completion of the transactions contemplated by the purchase agreement is subject to customary closing conditions, including the parties having received certain third-party consents and approvals.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "Last fall, we put forth our new focused business strategy which included identifying non-core assets and actively seeking to divest them as a way to infuse non-dilutive funds into the Company. We are very pleased to have entered into an agreement for the sale of the compound, miltefosine, and look forward to consummating the deal in the near future."

"This transaction marks the first time that Paladin has acquired international rights to a patented, medically important product", said Jonathan Ross Goodman, President and CEO of Paladin Labs. "This transaction is expected to be immediately accretive to earnings and it fits within our broader strategy to grow Paladin's revenues beyond the Canadian border."

About miltefosine

Miltefosine
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
2. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
3. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
4. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
5. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
8. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
9. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
10. DW Healthcare Partners Announces the Sale of Tandem Labs
11. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are less ... travel range with closed-loop sensor resolution up to ... new positioners the ideal choice for high precision ... is also available. , More Information: Specifications ... found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , Reference-Class ...
(Date:5/23/2013)... 2013 BioTrends Research Group, one of ... specialized biopharmaceutical issues, finds that, unaided, one in ... reported that in the past six months, they ... in anticipation of the next generation of HCV ... only 6 percent reported that they had begun ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... molecules that appear in the central region of ,macromolecules ... atom ,at their center that determines their specific function. ... molecular electronics lies in their "ease of transfer ,electrons ... the work at the Nanomaterials and Nanotechnology Research Center ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Friday, September 9, 2011 at 10:55 a.m. EDT (7:55 a.m. ... Hotel in Boston.  Steve Worland, Ph.D., President and Chief Executive ... its clinical development programs, setrobuvir and ANA773. Dr. ...
... (NYSE Amex: CUR ) announced that President ... Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 ... opportunities and advancements in neural stem cell pharmaceuticals and ... the ongoing ALS trial at Emory University. ...
Cached Biology Technology:The quantum tunneling effect leads electron transport in porphyrins 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 2Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 3
(Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2
... jumps out of the bushes, youre still surprised. But your ... have begun to distinguish the circuitry in the brains emotion ... aversive or reward valence of a stimulus. C. Daniel ... 2007 issue of the journal Neuron, published by Cell Press. ...
... trenches in the First World War, but nearly a century ... discovered that phosgene is present in significant quantities in the ... well after the Second World War, but its continued presence ... used in the chemical industry. A team, including ...
... emissions should quickly reduce mercury levels in lake fish, ... the Proceedings of the National Academy of Science. The ... rates relevant to atmospheric deposition resulted in a significant ... only three years. This is good news. ...
Cached Biology News:How the brain handles surprise, good and bad 2Scientists in first global study of 'poison' gas in the atmosphere 2New study shows fish respond quickly to changes in mercury deposition 2New study shows fish respond quickly to changes in mercury deposition 3
...
SHEEP ANTI ESCHERICHIA COLI...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Multi-Sample Freezing-point Osmometer for 30 L samples, featuring 24-position turntable. Provides up to 30 minutes ... and software for statistical analysis and record keeping. RS-232 port. ... ... ...
Biology Products: